Polymorphous immunotherapy-induced cutaneous sarcoidosis Authors: Lucy Mackie, Monica Terlizzo, Nicolo Battisti, Kara Heelan, Silvia Aguilar-Duran Published: 2026 ABSTRACT We describe a patient who developed a cutaneous sarcoidosis-like reaction while on pembrolizumab, with both a facial lupus pernio-like rash and large subcutaneous nodules (Darier-Roussy disease) on her limbs. Case report A 68-year-old woman with a history of breast cancer presented with a nontender subcutaneous nodule on the forehead and a cluster of erythematous plaques on the nose (Figure 1). Over a few weeks she also developed tender nodules on the forearms (Figure 2) and knees, up to 4 cm in diameter. She felt well, without any systemic symptoms. Facial lupus pernio-like rash. Subcutaneous nodules on the forearm. She was being treated for a triple-negative grade 3 invasive ductal left breast cancer, diagnosed in 2023. In August 2023 she started neoadjuvant carboplatin, paclitaxel, epirubicin, cyclophosphamide and pembrolizumab. After eight cycles, in February 2024, she completed her course of chemotherapy but remained on pembrolizumab. In March she underwent a wide local excision and sentinel lymph node biopsy. Following that she received adjuvant radiotherapy, with the last cycle of pembrolizumab held during this time. She then presented with her eruption. She had no other medical conditions, aside from having undergone a hysterectomy 30 years prior. She had previously had a maculopapular rash with flucloxacillin. Blood tests showed an elevated C-reactive peptide (160 mg dL–1), with an elevated serum angiotensin-converting enzyme (103 µg L–1) and a weak homogenous staining pattern 1/80 for antinuclear antibodies. Other autoimmune and rheumatoid markers were normal. T spot to tuberculosis was negative. Computed tomography showed mediastinal lymphadenopathy, including in the hilar regions. Positron emission tomography (PET) also showed bilateral inflammatory changes in the lungs. A 6-mm punch biopsy from nodules on the left forearm revealed numerous noncaseating epithelioid granulomas with no significant lymphocytic infiltrate (Figure 3). A biopsy from the facial lesions was not performed, as it was thought clinically that these would show the same pathology. Noncaseating epithelioid granulomas. A 6-mm punch biopsy of the left forearm [haematoxylin and eosin, original magnification ×20 (inset ×40)]. The patient was diagnosed with a sarcoidosis-like reaction to pembrolizumab, and is the first case reported with a combination of lupus pernio and Darier-Roussy features induced by immunotherapy. Discussion Immunotherapy is an anticancer therapy that aims to harness the immune system to recognize and fight cancer. Our immune responses are regulated to prevent damage to healthy ‘self’ tissue. However, some cancerous cells exploit downregulation pathways and evade detection, which immunotherapy drugs block. Pembrolizumab was approved in 2014 and targets the programmed cell death-1 (PD-1) receptor on T cells. Immunotherapy is well recognized to cause a variety of immune-related adverse effects (irAEs). These include cutaneous reactions (cirAEs), reported in a recent systematic review to affect 22.4% of those receiving PD-1 therapy.1 Cutaneous sarcoidosis-like reactions (SLRs) are one of the less common cirAEs. SLRs are inflammatory granulomatous reactions that resemble sarcoidosis, an immunological disorder characterized by noncaseating granulomas.2 The pathogenesis of sarcoidosis is not fully understood but involves a cell-mediated immune reaction that immunotherapy probably affects. Sarcoidosis can have diverse systemic and cutaneous manifestations. There are around 18 cases of cutaneous SLRs to pembrolizumab described since 2016, mostly in patients treated for melanoma. Some of these occurred after months, or even discontinuation, of treatment.3 Most of these reactions involve subcutaneous nodules (normally a rare presentation), with others including changes to scars, facial rashes, erythema nodosum, dermal melanosis and a dermatomyositis-like rash.2,4,5 Most patients, like ours, also demonstrate lung involvement and bihilar lymphadenopathy.2 Lymphadenopathy can mimic cancer-related activity, with subcutaneous nodules also appearing as hypermetabolic on PET, so it is important to consider sarcoidosis in the differential.4 A full work-up for systemic sarcoidosis is needed. Most cases of SLR show a rapid resolution, sometimes without any treatment or stopping immunotherapy.4,5 Our patient received topical steroids (clobetasone butyrate 0.05%) for the face, and a reducing course of 1 mg kg–1 oral prednisolone with resolution of the cutaneous symptoms. Pembrolizumab was discontinued in our patient, but as she only had one cycle left, this was not deemed to have a substantial detrimental impact on her cancer management. In conclusion, this case describes a combined cutaneous ­sarcoidosis-like reaction to pembrolizumab. Prompt recognition is key as such reactions are rare, impact on quality of life and can mimic cancer activity.